Pfizer gets three-year reprieve from Trump pharma tariffs

Pfizer Inc CEO Albert Bourla, the company’s President Donald Trump on the pharmaceutical agreement with an agreement with the company’s US drug prices to reduce a part of a three -year capital, he said.

Pfizer will directly sell an average 50% discount on a website to the consumer directly to the consumer, TrumpXX, which aims to allow Americans to pay for prescriptions at discounted rates negotiated by the government.

The agreement seems to be solving the two major threats Pfizer faces. It will eliminate more harmful drug pricing policies while protecting the company from the future tariffs brought by the investigation investigation on whether the company represents a national security threat.
This is the latest example of the processing nature of tariff exemptions from Trump, which has unilaterally commercial policy to implement power on multiple industries. As with last week, Trump threatened 100% tariffs in the pharmaceutical industry.